# US 2023/0404982 A1 · Use of fk506 for the treatment of pulmonary arterial hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404982 A1
- Document ID: US20230404982A1
- Status: Published application
- Kind: A1
- Application number: 18/151,028
- Filed: 2023-01-06
- Published: 2023-12-21
- Earliest claimed: 2011-05-02
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Edda SPIEKERKOETTER; Marlene RABINOVITCH; Philip A. BEACHY; David SOLOW-CORDERO
- Web page: https://patentgrep.com/patent/US20230404982A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61P 9/12: Antihypertensives
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method of treating pulmonary arterial hypertension in a patient in need thereof, the method comprising: administering FK506 to the patient at a daily dosage of 0.002 mg/kg of the patient's weight to 0.05 mg/kg of the patient's weight.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of 0.05 ng/mL to 1 ng/mL.

### Claim 11 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of 0.1 ng/mL to 0.2 ng/mL.

### Claim 12 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of 0.2 ng/mL to 2 ng/mL.

### Claim 13 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of 1.5 ng/mL to 2.5 ng/mL.

### Claim 14 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of 3 ng/mL to 5 ng/mL.

### Claim 15 (depends on 9)

The method of claim 9, wherein the dosage provides an FK506 blood concentration of FK506 of below 1 ng/mL.

### Claim 16 (depends on 9)

The method of claim 9, further comprising administering the FK506 in combination with a therapeutically effective amount of at least one additional active compound.

### Claim 17 (depends on 16)

The method of claim 16 where the at least one additional active compound is one or more selected from the following list: sildenafil, bosentan, ambrisentan, epoprostenol, tadalafil, treprostinil iloprost, treprostinil, isosorbide dinitrate, or isosorbide dinitrate.

### Claim 18 (depends on 16)

The method of claim 16 where the at least one additional active compound is one or more selected from the following list: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, high-dose calcium channel blockers, antigoagulants, diuretics and antiproliferative agents.

### Claim 19

A method of treating pulmonary arterial hypertension in a patient in need thereof, the method comprising: administering FK506 to the patient at a daily dosage of 0.001 mg/kg of the patient's weight to 0.01 mg/kg of the patient's weight.

### Claim 20 (depends on 19)

The method of claim 19, wherein the dosage provides an FK506 blood concentration of 0.05 ng/mL to 1 ng/mL.

### Claim 21 (depends on 19)

The method of claim 19, wherein the dosage provides an FK506 blood concentration of FK506 of below 1 ng/mL.
